RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer
Prnewswire· 2025-07-02 00:00
Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and Ramsay Hospital Research FoundationPrecision medicine approach: The 60-patient Phase 2 study uses the PCPro™ lipid biomarker test to identify patients with poor prognosis most likely to benefit from the combinationLed by Professor Lisa Horvath, the study is expected to recruit people at sites across Australia and New ZealandProstate cancer is the s ...
Egide: Exit from the "Penalty Bench" compartment as of July 2nd, 2025
Globenewswire· 2025-07-02 00:00
Bollène (France), July 1st, 2025 – 06 :00pm (CET)Press Release Return to normal trading onEuronext Growth Paris™ Exit from the "Penalty Bench" compartment as of July 2nd, 2025 Egide Group (Euronext Growth Paris™- ISIN: FR0000072373 - Ticker: ALGID), worldwide provider of hermetic packages and connectors and heat dissipation solutions for sensitive electronic components, announces that its shares will return to normal trading as of July 2nd, 2025. Following the publication of its 2024 Annual Financial Report ...
IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2025
Globenewswire· 2025-07-02 00:00
Aggregated presentation by day and by market Statement of transactions in own shares from June 23rd to June 27th 2025 Name of the issuer Identity code of the issuer (Legal Entity Identifier) Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) IPSEN 549300M6SGDPB4Z94P11 23/06/2025 FR0010259150 335 100,58955 AQEU IPSEN 549300M6SGDPB4Z94P11 23/06/2025 FR0010259150 ...
Anterix: Wide Spectrum Coverage And Robust Balance Sheet To Justify Upside
Seeking Alpha· 2025-07-01 23:59
As one of the largest specialized spectrum holders of private LTE networks across the US, Anterix, Inc. (NASDAQ: ATEX ) continues to enjoy its domestic popularity and market presence. Its strong performance in recent quarters demonstrates its ability toI have been working in the logistics sector for almost two decades. I have been into stock investing and macroeconomic analysis for almost a decade. Currently, I focus on ASEAN and NYSE/NASDAQ Stocks, particularly in banks, telco, logistics, and hotels. Since ...
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Petco Health and Wellness Company, Inc. (WOOF)
GlobeNewswire News Room· 2025-07-01 23:58
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired Petco Health and Wellness Company, Inc. (“Petco” or the “Company”) (NASDAQ: WOOF) securities between January 14, 2021 and June 5, 2025, both dates inclusive (the “Class Period”). The Complaint alleges that Defendants made false a ...
HOOD Launches Tokenized Stocks in EU: Betting on Digital Asset Boom?
ZACKS· 2025-07-01 23:56
Key Takeaways Robinhood now offers tokenized U.S. stocks and ETFs to EU clients with zero commissions and 24/5 access. HOOD's crypto DARTs jumped 66.7% in May 2025, signaling rising investor activity and demand. HOOD's EU expansion, Bitstamp and WonderFi deals, and MiCA pursuits deepen its crypto ecosystem.Robinhood Markets, Inc. (HOOD) has introduced U.S. stock and exchange-traded fund (ETF) tokens for European Union (EU) investors. This will enable eligible HOOD clients to gain exposure to U.S. equities ...
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease
ZACKS· 2025-07-01 23:50
Key Takeaways BIIB has started phase III dosing of felzartamab for primary membranous nephropathy in a global study. The PROMINENT study will compare felzartamab to tacrolimus in 180 moderate-to-high-risk PMN patients. Felzartamab showed antibody reduction and improved kidney markers in earlier phase II PMN studies.Biogen (BIIB) initiated dosing in a global, late-stage study of its investigational candidate, felzartamab, for treating adult patients with primary membranous nephropathy (PMN). Top-line data ...
Does Joby Aviation's Milestone in Dubai Point Toward Further Growth?
ZACKS· 2025-07-01 23:45
Key Takeaways JOBY jumped after piloted eVTOL flights in Dubai, marking a milestone in its push toward commercialization. JOBY plans to develop facilities capable of producing up to 500 eVTOL aircraft annually in Dayton. JOBY stock is up 29.8% YTD, outperforming its industry despite trading at a premium price-to-book valuation.Shares of Joby Aviation (JOBY) , a leading player in the electric vertical takeoff and landing (eVTOL) space, gained in double digits on June 30 following the announcement that its ...
ARGAN: RENTAL INCOME UP +8% IN THE 1ST HALF OF 2025
Globenewswire· 2025-07-01 23:45
Quarterly financial information – Neuilly-sur-Seine, Tuesday, July 1, 2025 – 5.45 pm Rental income up +8% in the 1st half of 2025 Rental income (IFRS) at June 30, 2025 (non-audited figures) € million Year 2025 Year 2024 Trends 1st quarter (Jan. - March) 52.9 48.1 +10% 2nd quarter (April - June) 52.9 50.0 +6% Total 1st half 105.8 <td style="width:113.4px;;text-align: center ; vertical-align: middle; border-top: solid ...
Detailed information on share buyback transactions on June 24, 2025
Globenewswire· 2025-07-01 23:45
- Attachment Detailed information on share buyback transactions on June 24, 2025 ...